Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
NCT00057343 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400
Last updated 2006-09-12
Summary
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
- DRUG
-
Zevalin (ibritumomab tiuxetan)
- DRUG
-
Rituxan (rituximab)
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-03-31
Countries
- United States
Study Locations
More Related Trials
-
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
NCT00493454 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
NCT00732498 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
NCT00607854 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy
NCT00859001 ·Status: COMPLETED ·Phase: PHASE2
-
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
NCT00438581 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
NCT00384111 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
NCT01510184 ·Status: TERMINATED ·Phase: PHASE3
-
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00062114 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
NCT00031642 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
NCT00807196 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
NCT00290511 ·Status: COMPLETED ·Phase: PHASE2
-
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
NCT00582166 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma
NCT01493479 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
NCT00397800 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
NCT01662102 ·Status: TERMINATED ·Phase: PHASE3
-
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
NCT00193440 ·Status: COMPLETED ·Phase: PHASE2
-
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
NCT00220285 ·Status: COMPLETED ·Phase: PHASE2
-
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00073957 ·Status: COMPLETED ·Phase: PHASE2
-
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
NCT00453102 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy
NCT00850512 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
NCT00110149 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
NCT00185393 ·Status: COMPLETED ·Phase: PHASE3
-
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
NCT00336843 ·Status: COMPLETED ·Phase: PHASE2
-
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00033423 ·Status: TERMINATED ·Phase: PHASE1
-
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
NCT00902525 ·Status: TERMINATED ·Phase: PHASE2